

Influence of tau PET, amyloid PET, and hippocampal volume on cognitive decline in Alzheimer disease

Neurology

91, e859-e866

DOI: [10.1212/WNL.0000000000006075](https://doi.org/10.1212/WNL.0000000000006075)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 72, 177-185.	1.5	42
2	18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1197-1207.	1.2	48
3	Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease. <i>NeuroImage</i> , 2019, 201, 116043.	2.1	38
4	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. <i>NeuroImage: Clinical</i> , 2019, 23, 101895.	1.4	28
5	Predicting Risk for Dementia: Is It Ready for the Clinic?. <i>American Journal of Psychiatry</i> , 2019, 176, 501-502.	4.0	3
6	AD molecular: Imaging tau aggregates with positron emissions tomography. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 107-138.	0.9	10
7	Do anti-amyloid- β drugs affect neuropsychiatric status in Alzheimer's disease patients?. <i>Ageing Research Reviews</i> , 2019, 55, 100948.	5.0	24
8	Tau pathology in cognitively normal older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 637-645.	1.2	37
9	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , 2019, 179, 312-339.	13.5	1,675
10	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, S145-S176.	1.2	26
11	The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. <i>Nature Communications</i> , 2019, 10, 1766.	5.8	68
12	Association of Cortical β -Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 818.	4.5	25
13	Naproxen for presymptomatic Alzheimer disease. <i>Neurology</i> , 2019, 92, 829-830.	1.5	11
14	A walk through tau therapeutic strategies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 22.	2.4	211
15	A promising structural magnetic resonance imaging assessment in patients with preclinical cognitive decline and diabetes mellitus. <i>Journal of Cellular Physiology</i> , 2019, 234, 16838-16846.	2.0	5
16	The MemTrax Test Compared to the Montreal Cognitive Assessment Estimation of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1045-1054.	1.2	23
17	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	3.7	122
18	Progressive supranuclear palsy. <i>International Review of Neurobiology</i> , 2019, 149, 49-86.	0.9	19

#	ARTICLE	IF	CITATIONS
19	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	1.5	46
20	Upregulated levels and pathological aggregation of abnormally phosphorylated Tau-protein in children with neurodevelopmental disorders. Neuroscience and Biobehavioral Reviews, 2019, 98, 1-9.	2.9	23
21	Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome. Developmental Neurobiology, 2019, 79, 711-715.	1.5	15
22	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	1.0	163
23	Association between personality and tau-PET binding in cognitively normal older adults. Brain Imaging and Behavior, 2020, 14, 2122-2131.	1.1	21
24	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain, 2020, 143, 320-335.	3.7	100
25	Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. Neurology, 2020, 94, e397-e406.	1.5	93
26	Determinants of mesial temporal lobe volume loss in older individuals with preserved cognition: a longitudinal PET amyloid study. Neurobiology of Aging, 2020, 87, 108-114.	1.5	9
27	In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice. Journal of Alzheimer's Disease, 2020, 73, 147-161.	1.2	10
28	Amyloid- β -independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience, 2020, 21, 21-35.	4.9	338
29	The Imaging Features and Clinical Associations of a Novel Tau PET Tracer ¹⁸ F-APN1607 in Alzheimer Disease. Clinical Nuclear Medicine, 2020, 45, 747-756.	0.7	20
30	Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions. BMJ, The, 2020, 371, m3684.	3.0	36
31	Long-Term Exposure to PM10 and in vivo Alzheimer's Disease Pathologies. Journal of Alzheimer's Disease, 2020, 78, 745-756.	1.2	16
32	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	1.4	17
33	MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129697.	1.1	6
34	Nrf2: a dark horse in Alzheimer's disease treatment. Ageing Research Reviews, 2020, 64, 101206.	5.0	131
35	Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. Seminars in Ultrasound, CT and MRI, 2020, 41, 572-583.	0.7	12
36	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. Neurology, 2020, 95, e3104-e3116.	1.5	35

#	ARTICLE	IF	CITATIONS
37	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
38	Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1203-1210.	1.2	7
39	Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. <i>Brain</i> , 2020, 143, 1588-1602.	3.7	113
40	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. <i>Cerebral Cortex</i> , 2020, 30, 5686-5701.	1.6	22
41	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1119-1129.	1.2	14
42	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574.	1.1	7
43	Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk. <i>Neurobiology of Disease</i> , 2020, 138, 104788.	2.1	23
44	Subtle voices, distant futures: a critical look at conditions for patient involvement in Alzheimer's biomarker research and beyond. <i>Journal of Responsible Innovation</i> , 2020, 7, 170-192.	2.3	9
45	Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity. <i>Brain Communications</i> , 2020, 2, fcz046.	1.5	53
46	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 347.	5.8	185
47	Reshaping the Amyloid Buildup Curve in Alzheimer Disease? Partial-Volume Effect Correction of Longitudinal Amyloid PET Data. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1820-1824.	2.8	7
48	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. <i>Biochemical Pharmacology</i> , 2020, 177, 113945.	2.0	62
49	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	3.3	29
50	Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. <i>Biological Psychiatry</i> , 2021, 89, 786-794.	0.7	48
51	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. <i>Journal of Cognitive Neuroscience</i> , 2021, 33, 279-302.	1.1	10
52	Association of Initial A β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	4.5	27
53	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β -negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021, 97, 41-48.	1.5	23
54	Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. <i>Journal of Neuroscience</i> , 2021, 41, 366-375.	1.7	29

#	ARTICLE	IF	CITATIONS
55	Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories. <i>NeuroImage: Clinical</i> , 2021, 31, 102713.	1.4	6
56	Longitudinal cognitive performance of Alzheimer's disease neuropathological subtypes. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12201.	1.8	7
57	Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2283-2294.	3.3	9
58	The neuroimaging of neurodegenerative and vascular disease in the secondary prevention of cognitive decline. <i>Neural Regeneration Research</i> , 2021, 16, 1490.	1.6	2
59	Pathobiology and Management of Alzheimer's Disease. <i>Chonnam Medical Journal</i> , 2021, 57, 108.	0.5	4
60	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2200-2211.	3.3	19
61	Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. <i>Brain Sciences</i> , 2021, 11, 215.	1.1	58
63	Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to A β ² and tau PET. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 36.	3.0	10
64	Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease. <i>Neurotherapeutics</i> , 2021, 18, 709-727.	2.1	9
65	Relationship between brain AD biomarkers and episodic memory performance in healthy aging. <i>Brain and Cognition</i> , 2021, 148, 105680.	0.8	13
66	Brain Molecular Connectivity in Neurodegenerative Conditions. <i>Brain Sciences</i> , 2021, 11, 433.	1.1	7
67	Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 74.	3.0	33
68	Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. <i>Clinical and Translational Medicine</i> , 2021, 11, e397.	1.7	22
69	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. <i>Journal of Nanobiotechnology</i> , 2021, 19, 122.	4.2	60
70	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
71	Alzheimer's disease. <i>Lancet</i> , 2021, 397, 1577-1590.	6.3	1,530
72	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
73	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021, 32, 849-860.	1.8	8

#	ARTICLE	IF	CITATIONS
74	The Effects of Amyloid and Tau on Functional Network Connectivity in Older Populations. <i>Brain Connectivity</i> , 2021, 11, 599-612.	0.8	7
75	Structural Changes in Thalamic Nuclei Across Prodromal and Clinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 361-371.	1.2	16
76	Polyphenol-Peptide Interactions in Mitigation of Alzheimer's Disease: Role of Biosurface-Induced Aggregation. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 33-55.	1.2	4
77	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1998-2008.	0.4	25
78	Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. <i>Current Neuropharmacology</i> , 2022, 20, 713-737.	1.4	8
79	Positive Effect of Cognitive Reserve on Episodic Memory, Executive and Attentional Functions Taking Into Account Amyloid-Beta, Tau, and Apolipoprotein E Status. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 666181.	1.7	7
80	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 3825.	5.8	29
81	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. <i>Neurobiology of Aging</i> , 2021, 102, 151-160.	1.5	6
83	Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. <i>Brain and Cognition</i> , 2021, 152, 105749.	0.8	9
84	Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 137.	3.0	59
85	Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. <i>Brain Pathology</i> , 2022, 32, e13016.	2.1	13
86	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24
88	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 153.	3.0	3
89	Cross-sectional associations of tau protein biomarkers with semantic and episodic memory in older adults without dementia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2021, 71, 101449.	5.0	6
90	Potential neuroprotection by <i>Dendrobium nobile</i> Lindl alkaloid in Alzheimer's disease models. <i>Neural Regeneration Research</i> , 2022, 17, 972.	1.6	25
91	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, 501-511.	0.4	47
92	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
93	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 294-300.	0.5	3

#	ARTICLE	IF	CITATIONS
95	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019, 8, .	2.8	57
96	Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 167.	3.0	8
101	Clinical Research Progress of Alzheimer's Disease. <i>Advances in Clinical Medicine</i> , 2020, 10, 2254-2259.	0.0	0
102	Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts. <i>NeuroImage: Clinical</i> , 2022, 33, 102900.	1.4	8
103	Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 415-429.	1.2	15
104	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 196.	3.0	13
105	Mechanistic and therapeutic implications of EphA4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5532-5546.	1.2	8
106	Can exercise training teach us how to treat Alzheimer's disease?. <i>Ageing Research Reviews</i> , 2022, 75, 101559.	5.0	23
107	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1951-1963.	3.3	8
108	Genetically identical twins show comparable tau PET load and spatial distribution. <i>Brain</i> , 2022, 145, 3571-3581.	3.7	12
109	Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 905-924.	1.2	3
110	Role of proline-rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5442-5452.	1.2	2
111	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5516-5531.	1.2	13
112	The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12284.	1.2	1
113	Grip Strength, Gait Speed and Plasma Markers of Neurodegeneration in Asymptomatic Middle-aged and Older Adults. <i>Journal of Frailty & Aging</i> , 2022, 0, , 1.	0.8	4
114	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 594-602.	1.3	2
115	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 306-318.	21.5	273
116	Redox signaling at the crossroads of human health and disease. <i>MedComm</i> , 2022, 3, e127.	3.1	44

#	ARTICLE	IF	CITATIONS
118	Plasma τ is associated with mild cognitive decline in patients with diabetes. <i>Psychogeriatrics</i> , 2022, 22, 353-359.	0.6	3
119	Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease. <i>Sleep</i> , 2022, 45, .	0.6	7
120	Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Neurology International</i> , 2022, 14, 357-367.	1.3	2
121	Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2022, 36, 15-21.	0.6	3
122	Medicinal Cannabis and Central Nervous System Disorders. <i>Frontiers in Pharmacology</i> , 2022, 13, 881810.	1.6	12
123	τ in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 66.	3.0	15
124	Commentary. <i>Clinical Nuclear Medicine</i> , 2022, 47, 707-709.	0.7	6
125	Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. <i>Neurobiology of Aging</i> , 2022, 117, 83-96.	1.5	3
126	PET Imaging in Animal Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, .	1.4	4
127	Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
128	The future of stem cell therapies of Alzheimer's disease. <i>Ageing Research Reviews</i> , 2022, 80, 101655.	5.0	5
129	Chronic vitamin D3 supplementation alleviates cognition impairment via inhibition of oxidative stress regulated by PI3K/AKT/Nrf2 in APP/PS1 transgenic mice. <i>Neuroscience Letters</i> , 2022, 783, 136725.	1.0	5
130	τ Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy. <i>Annals of Neurology</i> , 2022, 92, 425-438.	2.8	12
131	White matter lesions may be an early marker for age-related cognitive decline. <i>NeuroImage: Clinical</i> , 2022, 35, 103096.	1.4	13
132	Escalation of Tau Accumulation after a Traumatic Brain Injury: Findings from Positron Emission Tomography. <i>Brain Sciences</i> , 2022, 12, 876.	1.1	2
133	Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 633-640.	1.2	6
134	Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	3
135	Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum. <i>Neurology</i> , 2022, 99, .	1.5	14

#	ARTICLE	IF	CITATIONS
136	Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease. <i>Human Brain Mapping</i> , 2023, 44, 327-340.	1.9	2
138	Amyloid Conversion is Related to Risk Factors For Dementia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
140	Biomarkers for dementia in Latin American countries: Gaps and opportunities. <i>Alzheimer's and Dementia</i> , 2023, 19, 721-735.	0.4	15
142	A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2023, 19, 1452-1465.	0.4	1
143	Comparison of plasma and CSF biomarkers in predicting cognitive decline. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1739-1751.	1.7	20
144	Cerebral blood flow, tau imaging, and memory associations in cognitively unimpaired older adults. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100153.	0.4	1
145	A novel generation adversarial network framework with characteristics aggregation and diffusion for brain disease classification and feature selection. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	1
147	PET molecular imaging for pathophysiological visualization in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 765-783.	3.3	18
148	Frontal and temporal lobe correlates of verbal learning and memory in aMCI and suspected Alzheimer's disease dementia. <i>Aging, Neuropsychology, and Cognition</i> , 2023, 30, 923-939.	0.7	6
149	APOE ϵ 4 genotype, amyloid- β , and sex interact to predict tau in regions of high APOE mRNA expression. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	13
150	Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	0
151	Hierarchical Two-Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer's Disease and Related Dementias. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 895-909.	1.2	3
152	Iron and Alzheimer's Disease. , 2023, , 139-170.		1
153	Medial temporal tau predicts memory decline in cognitively unimpaired elderly. <i>Brain Communications</i> , 2022, 5, .	1.5	5
154	Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. <i>Alzheimer's and Dementia</i> , 2023, 19, 2497-2507.	0.4	11
155	Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. <i>ELife</i> , 0, 12, .	2.8	15
156	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. <i>Neuropharmacology</i> , 2023, 229, 109478.	2.0	10
157	Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative. <i>Neurobiology of Aging</i> , 2023, 127, 33-42.	1.5	0

#	ARTICLE	IF	CITATIONS
158	Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging. Brain and Behavior, 2023, 13, .	1.0	4
159	Deciphering the genetic architecture of human brain structure and function: a brief survey on recent advances of neuroimaging genomics. Briefings in Bioinformatics, 2023, 24, .	3.2	3
168	The molecular pathology of neurodegenerative and psychiatric disorders. , 2023, , 3-43.		4
175	Pathological Roles of INPP5D in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2023, , 289-301.	0.8	0